GABARAPL1

Across TCGA pan-cancer cohorts, GABARAPL1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GABARAPL1 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GABARAPL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GABARAPL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where GABARAPL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.876	0.362	.001	16	view →
CCRCC	DFS	Median	II,III,IV	0.382	0.723	.016	10	view →
LSCC	OS	Tertile	III,IV	0.972	0.533	.040	6	view →
GBM	DFS	Median	All	0.420	0.826	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GABARAPL1–PDAC (DFS)

Open the PDAC breakdown →